Palvella Therapeutics (PVLA) Non Operating Income (2015 - 2024)
Palvella Therapeutics (PVLA) posted quarterly Non Operating Income of $169000.0 for Q3 2024, down 69.22% year-over-year from $549000.0 in Q4 2023, and down 15.92% quarter-over-quarter from $201000.0 in Q2 2024.
Palvella Therapeutics (PVLA) Non Operating Income (2015 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Non Operating Income for 9 consecutive years, with $169000.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Non Operating Income fell 69.22% year-over-year to $169000.0; the TTM figure through Sep 2024 stood at $1.1 million (down 39.04% YoY), while the FY2023 annual figure was $1.9 million, up 156.73% from the prior year.
- Non Operating Income eased to $169000.0 in Q3 2024 per PVLA's latest filing, from $201000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $549000.0 in Q3 2023 and bottomed at -$6000.0 in Q4 2021.
- Historically, Non Operating Income has averaged $194578.9 across 5 years, with a median of $169000.0 in 2024.
- Annual changes were most pronounced in 2022 — Non Operating Income plunged 200.0% — and 2023, when it jumped 12000.0%.
- Palvella Therapeutics' Non Operating Income stood at $8000.0 in 2020, then sank by 175.0% to -$6000.0 in 2021, then surged by 5950.0% to $351000.0 in 2022, then advanced by 29.63% to $455000.0 in 2023, then tumbled by 62.86% to $169000.0 in 2024.
- Business Quant data shows PVLA's Non Operating Income at $169000.0 in Q3 2024, $201000.0 in Q2 2024, and $240000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 169,000.00 |
| Jun 30, 2024 | 201,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Dec 31, 2023 | 455,000.00 |
| Sep 30, 2023 | 549,000.00 |
| Jun 30, 2023 | 490,000.00 |
| Mar 31, 2023 | 357,000.00 |
| Dec 31, 2022 | 351,000.00 |
| Sep 30, 2022 | 241,000.00 |
| Jun 30, 2022 | 132,000.00 |
| Mar 31, 2022 | -3,000.00 |
| Dec 31, 2021 | -6,000.00 |
| Sep 30, 2021 | 4,000.00 |
| Jun 30, 2021 | 3,000.00 |
| Mar 31, 2021 | 3,000.00 |
| Dec 31, 2020 | 8,000.00 |
| Sep 30, 2020 | 55,000.00 |
| Jun 30, 2020 | 129,000.00 |
| Mar 31, 2020 | 319,000.00 |
| Dec 31, 2019 | 382,000.00 |